•NSAID use may lower AMD risk•4DMT reports new phase 2b gene therapy data for wet AMD•Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study•Biocon launches Eylea biosimilar to US market•Claris Bio raises $118M to advance first-ever LSCD therapy•NSAID use may lower AMD risk•4DMT reports new phase 2b gene therapy data for wet AMD•Glaukos completes enrollment in PRESERFLO MicroShunt pivotal study•Biocon launches Eylea biosimilar to US market•Claris Bio raises $118M to advance first-ever LSCD therapy
HEADLINES
FEATURED
Eye care leaders gathered in Nashville for two days of candid talks and workshops on building stronger eyecare organizations.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
![[object Object]](/_next/image/?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F51cpf7jm%2Fproduction%2F0fbac34bad6d09f82e441f0027ebe861bc590ab8-1200x628.png%3Fw%3D2400%26q%3D100%26fit%3Dfill%26auto%3Dformat&w=3840&q=75)
